Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 701 to 725 of 1139 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
701 disrupted regulation of cell cycle (GO:0051726) cell cycle-related cyclin (PR:000029191) 1505: Cell cycle, disrupted
702 increased increased apoptosis (MP:0006042) apoptosis fated cell (CL:0000445) None
703 decreased spermatocyte (CL:0000017) 1515: Spermatocyte depletion
704 decreased testicular atrophy (MP:0003205) Testis (FMA:7210) None
705 decreased fatty acid beta-oxidation (GO:0006635) 1528: Fatty Acid Beta Oxidation, Decreased
706 decreased regulation of hormone levels (GO:0010817) thyroxine (CHEBI:30660) 280: Thyroxine (T4) in neuronal tissue, Decreased
707 morphological change brain development (GO:0007420) hippocampal formation (UBERON:0002421) 757: Hippocampal anatomy, Altered
708 abnormal chemical synaptic transmission (GO:0007268) synapse (GO:0045202) 758: Hippocampal Physiology, Altered
709 increased endocytosis (GO:0006897) lysosomal membrane (GO:0005765) 1539: Endocytotic lysosomal uptake
710 decreased abnormal circulating thyroxine level (MP:0005475) thyroxine (CHEBI:30660) 281: Thyroxine (T4) in serum, Decreased
711 decreased abnormal circulating hormone level (MP:0005418) 3,3',5'-triiodothyronine (CHEBI:28774) None
712 decreased abnormal circulating hormone level (MP:0005418) 3,3',5-triiodo-L-thyronine (CHEBI:18258) None
713 decreased abnormal circulating hormone level (MP:0005418) None
714 increased cellular response to oxidative stress (GO:0034599) 1394: Induction, persistent proliferation/sustained proliferation
715 increased macrophage activation involved in immune response (GO:0002281) macrophage (CL:0000235) 1394: Induction, persistent proliferation/sustained proliferation
716 decreased hypoxia (MP:0005039) hypoxia-inducible factor 1-alpha (PR:000008555) 1394: Induction, persistent proliferation/sustained proliferation
717 decreased hypoxia (MP:0005039) von Hippel-Lindau disease tumor suppressor (PR:000017294) 1394: Induction, persistent proliferation/sustained proliferation
718 decreased hypoxia-inducible factor-1alpha signaling pathway (GO:0097411) von Hippel-Lindau disease tumor suppressor (PR:000017294) None
719 increased hypoxia-inducible factor-1alpha signaling pathway (GO:0097411) None
720 decreased phagocytosis (GO:0006909) macrophage (CL:0000235) 1668: Frustrated phagocytosis
721 increased DNA molecule region (FMA:84119) None
722 disrupted tubulin complex (GO:0045298) 718: Binding, Tubulin
723 increased Testicular atrophy (HP:0000029) Testis (FMA:7210) 1506: Testicular atrophy
724 increased G-protein coupled acetylcholine receptor binding (GO:0031789) muscarinic acetylcholine receptor (PR:000001488) 1602: Increased Muscarinic Acetylcholine Receptors
725 increased Wnt protein secretion (GO:0061355) protein-serine O-palmitoleoyltransferase porcupine (PR:000030936) 1754: Increase, porcupine-induced Wnt secretion and Wnt signaling activation